KalVista Pharmaceuticals (KALV) Misses Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.92), $0.05 worse than the analyst estimate of ($0.87).
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Double Downgrades Gulfport Energy (GPOR) to Underweight
- Citi upgrades Old Dominion Freight Line to Buy with $223 target
- Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
